Trial Profile
Two-month Regimens Using Novel Combinations to Augment Treatment Effectiveness for drug-sensitive Tuberculosis (TB)
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 16 Aug 2023
Price :
$35
*
At a glance
- Drugs Bedaquiline (Primary) ; Clofazimine (Primary) ; Levofloxacin (Primary) ; Linezolid (Primary) ; Rifapentine (Primary) ; Ethambutol; Isoniazid; Pyrazinamide; Rifampicin
- Indications Pulmonary tuberculosis
- Focus Therapeutic Use
- Acronyms TRUNCATE-TB
- 22 Feb 2023 Status changed to completed, as per presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023
- 22 Feb 2023 Results of Efficacy and Safety of 8-Wk Tuberculosis Treatment Regimens, presented at the 30th Conference on Retroviruses and Opportunistic Infections 2023
- 27 Mar 2018 Status changed from not yet recruiting to recruiting.